SEC Comment Letter for Cellectis S.A. (CLLS) (CIK 0001627281) (CLLS) — Jun 29, 2022
Cellectis S.A. (CLLS) (CIK 0001627281)
Date: June 29, 2022 · CIK: 0001627281 · Accession: 0000000000-22-006980
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-265826
Letter
United States securities and exchange commission logo June 29, 2022 André Choulika Chief Executive Officer and Director Cellectis S.A. 8, rue de la Croix Jarry 75013 Paris, France Re:Cellectis S.A. Registration Statement on Form F-3 Filed June 24, 2022 File No. 333-265826 Dear Dr. Choulika: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Gary Guttenberg at (202) 551-6477 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Peter Devlin
Show Raw Text
United States securities and exchange commission logo
June 29, 2022
André Choulika
Chief Executive Officer and Director
Cellectis S.A.
8, rue de la Croix Jarry
75013 Paris, France
Re:Cellectis S.A.
Registration Statement on Form F-3
Filed June 24, 2022
File No. 333-265826
Dear Dr. Choulika:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Gary Guttenberg at (202) 551-6477 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Peter Devlin